Gabapentin enacarbil
| Title | Journal |
|---|---|
| ADMET considerations for restless leg syndrome drug treatments. | Expert opinion on drug metabolism & toxicology 20121001 |
| Dose response of Gabapentin Enacarbil versus placebo in subjects with moderate-to-severe primary restless legs syndrome: an integrated analysis of three 12-week studies. | CNS drugs 20120901 |
| The treatment of restless legs syndrome and periodic limb movement disorder in adults--an update for 2012: practice parameters with an evidence-based systematic review and meta-analyses: an American Academy of Sleep Medicine Clinical Practice Guideline. | Sleep 20120801 |
| [Pharmacological and clinical profile of gabapentin enacarbil: a novel drug for the treatment of restless legs syndrome]. | Nihon yakurigaku zasshi. Folia pharmacologica Japonica 20120801 |
| Long-term efficacy and safety of gabapentin enacarbil in Japanese restless legs syndrome patients. | Progress in neuro-psychopharmacology & biological psychiatry 20120330 |
| Gabapentin enacarbil for treatment of restless legs syndrome in adults. | The Annals of pharmacotherapy 20120201 |
| Evaluation of gabapentin enacarbil on cardiac repolarization: a randomized, double-blind, placebo- and active-controlled, crossover thorough QT/QTc study in healthy adults. | Clinical therapeutics 20120201 |
| Clinical pharmacokinetics of gabapentin after administration of gabapentin enacarbil extended-release tablets in patients with varying degrees of renal function using data from an open-label, single-dose pharmacokinetic study. | Clinical therapeutics 20120101 |
| A randomized, double-blind, placebo-controlled, dose-response study to assess the pharmacokinetics, efficacy, and safety of gabapentin enacarbil in subjects with restless legs syndrome. | Clinical neuropharmacology 20120101 |
| Gabapentin enacarbil for the treatment of restless legs syndrome (RLS). | Expert opinion on pharmacotherapy 20111201 |
| Gabapentin encarbil (Horizant) for restless leg syndrome. | The Medical letter on drugs and therapeutics 20110905 |
| Randomized polysomnography study of gabapentin enacarbil in subjects with restless legs syndrome. | Movement disorders : official journal of the Movement Disorder Society 20110901 |
| Efficacy of gabapentin enacarbil vs placebo in patients with postherpetic neuralgia and a pharmacokinetic comparison with oral gabapentin. | Pain medicine (Malden, Mass.) 20110701 |
| A randomized, double-blind, placebo-controlled study to assess the efficacy and tolerability of gabapentin enacarbil in subjects with restless legs syndrome. | Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine 20110615 |
| A phase I, single-dose study of the disposition of 14C-radiolabeled gabapentin enacarbil in healthy male volunteers. | International journal of clinical pharmacology and therapeutics 20110201 |
| A 52-week study of gabapentin enacarbil in restless legs syndrome. | Clinical neuropharmacology 20110101 |
| Validation of the post sleep questionnaire for assessing subjects with restless legs syndrome: results from two double-blind, multicenter, placebo-controlled clinical trials. | BMC neurology 20110101 |
| Gabapentin enacarbil (XP13512/GSK1838262) as an alternative treatment to dopaminergic agents for restless legs syndrome. | Expert opinion on pharmacotherapy 20100801 |
| Long-term maintenance treatment of restless legs syndrome with gabapentin enacarbil: a randomized controlled study. | Mayo Clinic proceedings 20100601 |
| Clinical pharmacokinetic drug interaction studies of gabapentin enacarbil, a novel transported prodrug of gabapentin, with naproxen and cimetidine. | British journal of clinical pharmacology 20100501 |
| The effect of food with varying fat content on the clinical pharmacokinetics of gabapentin after oral administration of gabapentin enacarbil. | International journal of clinical pharmacology and therapeutics 20100201 |
| Gabapentin enacarbil in restless legs syndrome. | Drugs of today (Barcelona, Spain : 1998) 20100101 |
| Pharmacokinetics and tolerability of single escalating doses of gabapentin enacarbil: a randomized-sequence, double-blind, placebo-controlled crossover study in healthy volunteers. | Clinical therapeutics 20090801 |
| Randomized, double-blind, placebo-controlled study of XP13512/GSK1838262 in patients with RLS. | Neurology 20090203 |
| A randomized, double-blind, placebo-controlled, crossover study of XP13512/GSK1838262 in the treatment of patients with primary restless legs syndrome. | Sleep 20090201 |
| Gabapentin enacarbil, a gabapentin prodrug for the treatment of the neurological symptoms associated with disorders such as restless legs syndrome. | Current opinion in investigational drugs (London, England : 2000) 20090101 |
| Gabapentin enacarbil in restless legs syndrome: a phase 2b, 2-week, randomized, double-blind, placebo-controlled trial. | Clinical neuropharmacology 20090101 |
| Clinical pharmacokinetics of XP13512, a novel transported prodrug of gabapentin. | Journal of clinical pharmacology 20081201 |
| New antiepileptic drugs that are second generation to existing antiepileptic drugs. | Expert opinion on investigational drugs 20060601 |
| XP13512 [(+/-)-1-([(alpha-isobutanoyloxyethoxy)carbonyl] aminomethyl)-1-cyclohexane acetic acid], a novel gabapentin prodrug: I. Design, synthesis, enzymatic conversion to gabapentin, and transport by intestinal solute transporters. | The Journal of pharmacology and experimental therapeutics 20041001 |
| XP13512 [(+/-)-1-([(alpha-isobutanoyloxyethoxy)carbonyl] aminomethyl)-1-cyclohexane acetic acid], a novel gabapentin prodrug: II. Improved oral bioavailability, dose proportionality, and colonic absorption compared with gabapentin in rats and monkeys. | The Journal of pharmacology and experimental therapeutics 20041001 |